CompletedPhase 1NCT01902329
A Safety Study of SGN-CD33A in AML Patients
Studying Acute promyelocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Seagen Inc.
- Principal Investigator
- Phoenix Ho, MDSeagen Inc.
- Intervention
- HMA(drug)
- Enrollment
- 195 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2017
Study locations (14)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- City of Hope National Medical Center, Duarte, California, United States
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
- Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Cleveland Clinic, The, Cleveland, Ohio, United States
- Charles A. Sammons Cancer Center / Baylor University Medical Center, Dallas, Texas, United States
- MD Anderson Cancer Center / University of Texas, Houston, Texas, United States
- University of Utah, Salt Lake City, Utah, United States
- Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01902329 on ClinicalTrials.govOther trials for Acute promyelocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07563179Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaShenzhen University General Hospital
- RECRUITINGPHASE3NCT07504458Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaQuetzal Therapeutics
- RECRUITINGPHASE3NCT07223814Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)Stichting Hemato-Oncologie voor Volwassenen Nederland
- ACTIVE NOT RECRUITINGNANCT07187505Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic LeukemiaAnhui Medical University
- RECRUITINGPHASE3NCT07503730Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).First Affiliated Hospital Xi'an Jiaotong University
- ENROLLING BY INVITATIONNANCT06697327Daunorubicin + Cytarabine + Venetoclax in de Novo AMLAnhui Medical University
- RECRUITINGPHASE1NCT06313437Revumenib in Combination With 7+3 + Midostaurin in AMLRichard Stone, MD
- RECRUITINGPHASE3NCT06578247Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLDaiichi Sankyo